Accordingly, several phase I/phase II clinical trials with CXCR1/CXCR2 antagonists or monoclonal anti-CXCL8 antibodies have been completed for treatment of COPD, however with conflicting results so far (vide infra). This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.